aacp hero banner

Poster Presentations

NCOA OUTSTANDING FELLOW RECOGNITION

The North Carolina Oncology Association (NCOA) is proud to showcase the following fellows—and recipients of the NCOA Outstanding Fellow Recognition— for their important contributions to cancer care and their communities.

Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant

Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant

Pavan Kumar Tenneti Venkata, MD, et al., Levine Cancer Institute, Charlotte, NC
View Poster
ADAMTS13 Inhibitor as a Marker for Recurrence of Acquired Thrombotic Thrombocytopenic Purpura

ADAMTS13 Inhibitor as a Marker for Recurrence of Acquired Thrombotic Thrombocytopenic Purpura

Annum Faisal, MD, et al., East Carolina University, Greenville, NC
View Poster
Bone Health in Chronic Lymphocytic Leukemia

Bone Health in Chronic Lymphocytic Leukemia

Heather Wolfe, MD, Heather Wolfe, MD,
View Poster
Exploring the Role of PCSK9 in Regulating an Immune Excluded Microenvironment and Resistance to Immune Checkpoint Blockade in NSCLC

Exploring the Role of PCSK9 in Regulating an Immune Excluded Microenvironment and Resistance to Immune Checkpoint Blockade in NSCLC

James Isaacs, MD, et al., Duke University School of Medicine, Durham, NC
View Poster
Immunotherapy Experience in Nonagenarian Veterans with Cancer

Immunotherapy Experience in Nonagenarian Veterans with Cancer

Andrew Benefield, MD, et al., Wake Forest School of Medicine, Winston-Salem, NC
View Poster
Impact of COVID-19 Pandemic on Cancer Screening in Eastern North Carolina

Impact of COVID-19 Pandemic on Cancer Screening in Eastern North Carolina

Sukriti Kamboj, MD, et al., East Carolina University, Greenville, NC
View Poster
Machine Learning for Prospective Identification of Immunotherapy Related Adverse Events

Machine Learning for Prospective Identification of Immunotherapy Related Adverse Events

Dan Margalski, DO, et al., Wake Forest School of Medicine, Winston-Salem, NC
View Poster
Observed Survival Benefit with Limited Exposure of Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer at a Large Community-Based Institution

Observed Survival Benefit with Limited Exposure of Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer at a Large Community-Based Institution

Christopher R. Pallas, MD, et al., Levine Cancer Institute, Charlotte, NC
View Poster
Outcomes Associated with BEAM Conditioning Followed by Autologous Stem Cell Transplant in High-Risk Geriatric Patients

Outcomes Associated with BEAM Conditioning Followed by Autologous Stem Cell Transplant in High-Risk Geriatric Patients

Anne Wofford, MD, et al., Wake Forest School of Medicine, Winston-Salem, NC
View Poster
Peripheral Blood T Cell Responses to Immunotherapy Related Adverse Events in NSCLC Patients Treated with Immunotherapy

Peripheral Blood T Cell Responses to Immunotherapy Related Adverse Events in NSCLC Patients Treated with Immunotherapy

Suneetha Amara et al., East Carolina University, Greenville, NC
View Poster
Prevalence of Functional Deficits Among Adults with Multiple Myeloma and Normal Perceived Performance Status

Prevalence of Functional Deficits Among Adults with Multiple Myeloma and Normal Perceived Performance Status

Christopher Jensen, MD, et al., University of North Carolina School of Medicine, Chapel Hill, NC
View Poster
Racial Differences in Impact of Geography on Breast Cancer Treatment Delay

Racial Differences in Impact of Geography on Breast Cancer Treatment Delay

Jacquelyne Gaddy, MD, et al., University of North Carolina School of Medicine, Chapel Hill, NC
View Poster
Real-World Curative-Intent Treatment Patterns for Breast Cancer in an HIV-prevalent Malawian Cohort

Real-World Curative-Intent Treatment Patterns for Breast Cancer in an HIV-prevalent Malawian Cohort

Jennifer Morgan, MD, et al., University of North Carolina School of Medicine, Chapel Hill, NC
View Poster
Survival Outcomes with the Use of Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer at a Large Hybrid Cancer Institute

Survival Outcomes with the Use of Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer at a Large Hybrid Cancer Institute

Joanna A. Young, DO, et al., Levine Cancer Institute, Charlotte, NC
View Poster